Abstract: Provided are methods of isolating a novel cell population of midbrain dopaminergic neuronal progenitor cells derived from stem cells using a novel combination markers. The cell population may be used for cell therapies for the treatment of Parkinson's disease and as substrates in pharmacological assays.
Abstract: The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (PTSD) in subjects, e.g., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce a symptom of the anxiety disorder in the subject.
Abstract: A magnetic coil system featuring a multi-layer structure (312a, 312b), a spherical shape, or both allows for efficient generation of a gradient magnetic field that induces an electric field in air in a region proximate to the coil. By subjecting at least a portion of a person's brain to the induced electric field various psychiatric disorders can be treated.
Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegenerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.
Type:
Application
Filed:
January 12, 2017
Publication date:
July 27, 2017
Applicants:
UNIVERSITY OF DELHI, THE MCLEAN HOSPITAL CORPORATION
Inventors:
Diwan S. RAWAT, Sunny MANOHAR, Ummadisetty Chinna RAJESH, Deepak KUMAR, Anuj THAKUR, Mohit TRIPATHI, Panyala Linga REDDY, Shamseer Kulangara KANDI, Satyapavan VARDHINENI, Kwang-Soo KIM, Chun-Hyung KIM
Abstract: A system for convection enhanced delivery of therapeutic comprises one or more flexible, biocompatible microcatheters that are directed to a target location to deliver a therapeutic agent. The microcatheter is releasably coupled to a guide tube and directed to the desired location. The microcatheters are small and flexible in order to reach the target areas, minimize trauma at the injection site, and minimize reflux of the injectable therapeutic.
Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.
Type:
Grant
Filed:
February 28, 2013
Date of Patent:
February 14, 2017
Assignees:
THE MCLEAN HOSPITAL CORPORATION, UNIVERSITY OF DELHI
Inventors:
Diwan S. Rawat, Sunny Manohar, Ummadisetty Chinna Rajesh, Deepak Kumar, Anuj Thakur, Mohit Tripathi, Panyala Linga Reddy, Shamseer Kulangara Kandi, Satyapavan Vardhineni, Kwang-Soo Kim, Chun-Hyung Kim
Abstract: The invention features 2-alkoxy-11-hydroxyaporphine derivatives that selectively bind D2high receptors. The compounds are useful for imaging D2high receptors and for the treatment of diseases, such as Parkinson's disease, sexual dysfunction, and depressive disorders.
Type:
Grant
Filed:
April 14, 2011
Date of Patent:
December 13, 2016
Assignee:
The McLean Hospital Corporation
Inventors:
John L. Neumeyer, Yu-Gui Si, Anna W. Sromek
Abstract: A system and method for analyzing blood flow in a subject's brain is provided. In some aspects, the method includes analyzing fMRI data to identify signals related to blood flow, and selecting a zero time lag seed regressor using the identified signals. The method also includes correlating the selected seed regressor to identify a subset of the fMRI data that correlates with the seed regressor and is offset in time, combining the subset of the data to determine a time-delayed regressor, and performing repetitions to obtain a number of time-delayed regressors, where for each repetition, the seed regressor is adjusted using a previous time-delayed regressor. The method further includes analyzing the data using the time-delayed regressors to determine blood delivery from vessels across the brain, and generating a report. In some aspects, a second recursive procedure may be performed using an optimized seed regressor obtained from a first recursive procedure.
Abstract: Enhanced methods for the generation of medial ganglionic eminence (MGE) cells from pluripotent stem cells are provided that involve an additional step of contacting the cells with an activator of FGF8 signaling while differentiating Pax6? cells progenitor cells into MGE cells with an activator of sonic hedgehog, and optionally a Wnt inhibitor. The activator of FGF8 signaling shifts the differentiation of the population of cells to NKX2.1+MGE cells, rather than to CopuTFII+ caudal ganglionic eminence (CGE) cells. Methods for reatment of neurological disorders, such as epilepsy, by transplant of MGE cells, or GABAergic interneurons derived from human pluripotent stem cells, into a subject in need of treatment are also provided. Human pluripotent stem cell derived MGE cells when transplanted successfully suppress spontaneous seizures, e.g. in epilepsy.
Abstract: The inventions disclosed herein are based on the identification of novel cell populations derived from human embryonic stem cells and other pluripotent cells. The inventive cell populations may be used for cell therapies for the treatment of various neurological diseases and as substrates in pharmacological assays.
Abstract: The inventions disclosed herein are based on the identification of novel cell populations derived from human embryonic stem cells and other pluripotent cells. The inventive cell populations may be used for cell therapies for the treatment of various neurological diseases and as substrates in pharmacological assays.
Abstract: The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (PTSD) in subjects, e.g., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce a symptom of the anxiety disorder in the subject.
Abstract: The present invention provides populations of neural cells derived from pluripotent cells, and methods for making and using the same. Disclosed herein are methods for generating dopaminergic neurons in vitro using a combination of agents that cause differentiation of the pluripotent cells into dopaminergic neurons. Also disclosed are methods for treating a neurodegenerative disease in a patient by generating dopaminergic neurons in vitro, and transplanting them into the brain of the patient, such that the dopaminergic neurons are sufficient to reduce or eliminate the symptoms of the neurodegenerative disease.
Abstract: The invention features methods and systems to monitor changes in the magnitude of attentional disturbance and the magnitude of motor activity disturbance in a subject. The invention also features methods and systems for determining a subject's degree of concordance with individuals having an attentional disorder versus individuals not having an attentional disorder. The methods and systems of the invention can enable clinicians and consumers to ascertain both the severity of an attentional disorder as well as how much an individual changes over time, or with therapy.
Abstract: The invention features methods and systems for the diagnosis of ADHD and related disorders. The methods and systems of the invention can also be used to ascertain how much benefit an individual would derive from a particular therapy.
Abstract: Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome.
Type:
Application
Filed:
February 28, 2013
Publication date:
January 22, 2015
Applicant:
The McLean Hospital Corporation
Inventors:
Diwan S. Rawat, Sunny Manohar, Ummadisetty Chinna Rajesh, Deepak Kumar, Anuj Thakur, Mohit Tripathi, Panyala Linga Reddy, Shamseer Kulangara Kandi, Satyapavan Vardhineni, Kwang-Soo Kim, Chun-Hyung Kim
Abstract: A system for convection enhanced delivery of therapeutic comprises one or more flexible, biocompatible microcatheters that are directed to a target location to deliver a therapeutic agent. The microcatheter is releasably coupled to a guide tube and directed to the desired location. The microcatheters are small and flexible in order to reach the target areas, minimize trauma at the injection site, and minimize reflux of the injectable therapeutic.
Abstract: Provided are methods of isolating a novel cell population of midbrain dopaminergic neuronal progenitor cells derived from stem cells using a novel combination markers. The cell population may be used for cell therapies for the treatment of Parkinson's disease and as substrates in pharmacological assays.
Abstract: A system for convection enhanced delivery of therapeutic comprises one or more flexible, biocompatible microcatheters that are directed to a target location to deliver a therapeutic agent. The microcatheter is releasably coupled to a guide tube and directed to the desired location. The microcatheters are small and flexible in order to reach the target areas, minimize trauma at the injection site, and minimize reflux of the injectable therapeutic.
Abstract: The inventions disclosed herein are based on the identification of novel cell populations derived from human embryonic stem cells and other pluripotent cells. The inventive cell populations may be used for cell therapies for the treatment of various neurological diseases and as substrates in pharmacological assays.